A Phase 1B, Randomized, Placebo-Controlled, Double-Blinded, Dose-Escalation Study to Evaluate Safety, Tolerability and Pharmacokinetics of Single-Daily Doses of SQ109 in Normal, Healthy Male and Female Volunteers.
Phase of Trial: Phase I
Latest Information Update: 09 Jun 2011
At a glance
- Drugs SQ 109 (Primary)
- Indications Tuberculosis
- Focus Adverse reactions
- 13 Feb 2010 Actual patient number (10) added as reported by ClinicalTrials.gov.
- 13 Feb 2010 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 13 Feb 2010 Actual end date (Nov 2009) added as reported by ClinicalTrials.gov.